Another Cancer Research tells of falsified drug research

Fraud is rife in the world of drug research, according to C. Glenn Begley, a former head of global cancer research at drug giant Amgen. He has prepared a review of ’scientific studies’ in cancer research and reports on how 88 percent of 53 "landmark" studies on cancer that have been published in journals over the years cannot be reproduced. The author believes this means that their conclusions are patently false. The review was published in the journal Nature. 



In 47 out of 53 studies he examined the results could not be replicated in further studies. He accused researchers of ’Fabricating findings’ to increase grants, and increase project work on new drugs. As we tried to reproduce these papers we became convinced you can’t take anything at face value, Bergley added.



These findings are similar to those of scientists at Bayer who in 2011 reported that much of the published data upon which they might work to develop drugs could not be reproduced. Their report was entitled ’Believe it or not’. 



Begley says he cannot publish the names of the studies whose findings are false. But since it is now apparent that the vast majority of them are invalid, it only follows that the vast majority of modern approaches to cancer treatment are also invalid.



This is not the first study to come up with conclusions of fraud. For example, Dr. George Robertson from Dalhousie University found similar ’inconsistencies’ in published research studies on Parkinson’s disease and in 2009, researchers from the University of Michigan Comprehensive Cancer Centre published a review which concluded that many popular cancer studies were false. They concluded that vested interest lay behind the presentation of false results and that results were favoured that helped the Pharmaceutical companies rather than the patients. (http://www.naturalnews.com/026314_cancer_research_studies.html).








April - June Cancer Watch 2012
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.